Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24401671 | 0.81 | DPP4 (0.54) | KDM4EALDH1A1SMN1; SMN2HSD17B10CYP1A2 | |
| SCHEMBL32665417 | 0.81 | DYRK3 (0.58) | KDM4EALDH1A1SMN1; SMN2DYRK3CCNT1 | |
| SCHEMBL15365501 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1SMN1; SMN2DYRK3CCNT1 | |
| SCHEMBL12874554 | 0.79 | DYRK3 (0.60) | KDM4EALDH1A1SMN1; SMN2DYRK3CCNT1 | |
| SCHEMBL938269 | 0.79 | GABRG2 (0.53) | KDM4EALDH1A1HSD17B10CYP1A2CYP2C9 | |
| SCHEMBL103269 | 0.78 | DYRK1A (0.71) | DYRK3CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL5619274 | 0.78 | PIM1 (0.63) | KDM4ESMN1; SMN2CDK2HSD17B10CLK4 | |
| SCHEMBL4784567 | 0.78 | BRD4 (0.65) | KDM4EALDH1A1SMN1; SMN2CDK2DYRK1A | |
| SCHEMBL937443 | 0.76 | DPP4 (0.50) | KDM4EALDH1A1HSD17B10BRD4MET | |
| SCHEMBL15365361 | 0.76 | PIM1 (0.62) | KDM4EALDH1A1SMN1; SMN2CDK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7173033-B2 | Nitrogen-containing heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| CN-1281606-C | Nitrogen-containing heterocyclic compound | YAMANOUCHI PHARMA CO LTD (JP) | 2006-10-25 | — | — | CN | disclosed |
| US-20060173009-A1 | Agent inducing increase in bone mass | ASTELLAS PHARMA INC. (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1640010-A1 | AGENT INDUCING INCREASE IN BONE MASS | Astellas Pharma Inc. (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050261297-A1 | Nitrogen-containing heterocyclic compound | YAMANOUCHI PHARMACEUTICAL CO., LTD | 2005-11-24 | — | — | US | disclosed |
| CN-1639164-A | Nitrogen-containing heterocyclic compound | YAMANOUCHI PHARMA CO LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| US-20050096322-A1 | Nitrogen-containing heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1481977-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096322-A1 | Nitrogen-containing heterocyclic compound | BMP2, BMP1, BMP4 | KDM4E 2532/4885ALDH1A1 3344/4885SMN1; SMN2 1838/4885 |
| US-20050261297-A1 | Nitrogen-containing heterocyclic compound | BMP2, BMP1, BMP4 | KDM4E 2532/4885ALDH1A1 3344/4885SMN1; SMN2 1838/4885 |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | KDM4E 2541/4885ALDH1A1 2432/4885SMN1; SMN2 1673/4885 |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | KDM4E 2541/4885ALDH1A1 2432/4885SMN1; SMN2 1673/4885 |
| US-20060173009-A1 | Agent inducing increase in bone mass | SOST, CALCB, BMP4 | KDM4E 2584/4885ALDH1A1 4157/4885SMN1; SMN2 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.